Napo Pharmaceuticals announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease. Crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for MVID.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JAGX: